EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases

Javier Pagán-Escribano, Javier Corral, Antonia Miñano, José Padilla, Vanessa Roldán iD, María Julia Hernández-Vidal, Jesús Lozano, Isabel de la Morena-Barrio, Vicente Vicente iD, María Luisa Lozano iD, María Teresa Herranz, María Eugenia de la Morena-Barrio iD

International Journal of Molecular Sciences · 13.11.2023 · 24 (22) · 16270

DOI: 10.3390/ijms242216270 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.11.2023. Verfasst von Javier Pagán-Escribano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Interna, Unidad de Enfermedad Tromboembólica, Hospital General Universitario José María Morales Meseguer, 30008 Murcia, Spain. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Biomedical Network Research on Rare Diseases, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is a thromboinflammatory disorder caused by circulating antiphospholipid autoantibodies (aPL) and characterized by an increased risk of thrombotic events. The pathogenic mechanisms of these antibodies are complex and not fully understood, but disturbances in coagulation and fibrinolysis have been proposed to contribute to the thrombophilic state. This study aims to evaluate the role of an emerging hemostatic molecule, FXI, in the thrombotic risk of patients with aPL. Cross-sectional and observational study of 194 consecutive and unrelated cases with aPL recruited in a single center: 82 asymptomatic (AaPL) and 112 with primary antiphospholipid syndrome (APS). Clinical and epidemiological variables were collected. The profile of aPL was determined. Plasma FXI was evaluated by Western blotting and two coagulation assays (FXI:C). In cases with low FXI, molecular analysis of the F11 gene was performed. FXI:C levels were significantly higher in patients with APS than in patients with AaPL (122.8 ± 33.4 vs. 104.5 ± 27.5; p < 0.001). Multivariate analysis showed a significant association between symptomatic patients with aPL (APS) and high FXI (>150%) (OR = 11.57; 95% CI: 1.47–90.96; p = 0.020). In contrast, low FXI (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeThrombosisHumansFactor XICross-Sectional StudiesAntibodies, Antiphospholipid

Stichwörter der Autor:innen

antiphospholipid antibodiesantiphospholipid syndromecoagulationfactor XIthromboembolic disease

Substanzen

Factor XIAntibodies, Antiphospholipid

Autor:innen und Institutionen

  • Servicio de Medicina Interna, Unidad de Enfermedad Tromboembólica, Hospital General Universitario José María Morales Meseguer, 30008 Murcia, Spain.
  • Servicio de Hematología Hospital General Universitario José María Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, CEI Campus Mare Nostrum, 30003 Murcia, S…
  • Servicio de Reumatología, Hospital Clínico, 46010 Valencia, Spain.

ORCID-Profile: Vanessa Roldán, Vicente Vicente, María Luisa Lozano, María Eugenia de la Morena-Barrio

Förderung

  • Centre for Biomedical Network Research on Rare Diseases
  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación
  • Sociedad Española de Trombosis y Hemostasia
  • Center for Biomedical Research in Rare Diseases Network (CIBERER, from the Spanish Centro de Investigación Biomédica en Red de Enfermedades Raras)
  • Spanish Society of Thrombosis and Haemostasis (SETH: emerging groups)
  • Ministerio de Ciencia e Innovación, Spain

Zitieren

APA

Pagán-Escribano, J., Corral, J., Miñano, A., Padilla, J., Roldán, V., Hernández-Vidal, M. J., Lozano, J., de la Morena-Barrio, I., Vicente, V., Lozano, M. L., Herranz, M. T., & de la Morena-Barrio, M. E. (2023). Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases. International Journal of Molecular Sciences, 24(22), 16270. https://doi.org/10.3390/ijms242216270

Vancouver

Pagán-Escribano J, Corral J, Miñano A, Padilla J, Roldán V, Hernández-Vidal MJ, et al. Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases. International Journal of Molecular Sciences. 2023;24(22):16270. doi:10.3390/ijms242216270

BibTeX
@article{PagnEscribano2023,
  author = {Pagán-Escribano, Javier and Corral, Javier and Miñano, Antonia and Padilla, José and Roldán, Vanessa and Hernández-Vidal, María Julia and Lozano, Jesús and de la Morena-Barrio, Isabel and Vicente, Vicente and Lozano, María Luisa and Herranz, María Teresa and de la Morena-Barrio, María Eugenia},
  title = {Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {22},
  pages = {16270},
  doi = {10.3390/ijms242216270}
}
Kostenlos starten →